Skip to content
SPACListing
Browse
ScreenerFilingsMarketDeadlinesSponsorsBanksSectorsLearnPricingWatchlist
AnnouncedNasdaq

Translational Development Acquisition Corp.TDAC

Class A TDACUnits TDACUWarrants TDACWCIK 0001926599

Cash in trust

$157.3M

$157,261,867

Trust per share

Redemption value

IPO

Dec 2024

Combination deadline

Jun 24, 2027

293 days remaining

Filings on record

76

Latest Aug 14, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
May 27, 2026

Overview

Translational Development Acquisition Corp. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001926599. It completed its initial public offering in Dec 2024 and listing on Nasdaq. Class A shares trade under the ticker TDAC, units under TDACU, warrants under TDACW on Nasdaq. The vehicle is sponsored by TDAC through TDAC Partners LLC. The mandate targets generalist. Definitive business-combination agreement signed, closing pending.

we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business.
The mandate, as stated in the IPO prospectus

Reading the filings

Arithmetic on what Translational Development Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Time on the clock

    293 days to the Jun 24, 2027 deadline. The vehicle is early in its search window, and the deadline is not yet the binding constraint.

  • Warrant coverage

    Each unit carried one-half of one warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.

  • Underwriting

    BTIG led the offering. It has been named on 68 SPAC IPOs, book-running 63 of them, and 13.8% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

Scores

Recomputed 4m ago

Three readings of Translational Development Acquisition Corp., each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built

FOMO

Moderate

How much attention is this vehicle attracting right now?

47/100

  • Filing activity69

    4 in 30 days

  • News coverage0

    0 stories in 30 days

  • Deal freshness71

    announced 100 days ago

Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.

Potential

Elevated

How likely is this vehicle to complete a combination, and at what scale?

59/100

  • Lead bank record45

    13.8%

  • Bank franchise70

    68 SPAC mandates

  • Trust scale35

    $157M

  • Stage85

    definitive agreement signed

Potential is about execution, not about the target. It says nothing about whether the eventual deal is worth owning, because the target is usually unknown when the score is computed.

These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.

SEC filing history

Free tier: filings older than 24 hours
  • 10-Q

    Quarterly report

    Accession 0001104659-26-097093

    Aug 14, 2026

    20d ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001905106-26-000146

    Aug 14, 2026

    21d ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001193125-26-351225

    Aug 14, 2026

    21d ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000886982-26-000457

    Aug 12, 2026

    23d ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-330513

    Aug 3, 2026

    1mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-320984

    Jul 28, 2026

    1mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001104659-26-087089

    Jul 27, 2026

    1mo ago

    Open filing
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 3.02, 9.01 · Accession 0001104659-26-087086

    Jul 27, 2026

    1mo ago

    Open filing
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001140361-26-028660

    Jul 16, 2026

    1mo ago

    Open filing
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001104659-26-081579

    Jul 8, 2026

    1mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-286758

    Jun 29, 2026

    2mo ago

    Open filing
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001104659-26-076687

    Jun 23, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001104659-26-076686

    Jun 23, 2026

    2mo ago

    Open filing
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001104659-26-076684

    Jun 23, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-278623

    Jun 23, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-276612

    Jun 22, 2026

    2mo ago

    Open filing
  • 8-K

    Entry into a material definitive agreement; Submission of matters to a vote of security holders

    Items 1.01, 5.03, 5.07, 9.01 · Accession 0001104659-26-075471

    Jun 18, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-270239

    Jun 15, 2026

    2mo ago

    Open filing
  • 8-K

    Current report

    Item 3.02 · Accession 0001104659-26-073428

    Jun 12, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-265584

    Jun 10, 2026

    2mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001193125-26-252878

    Jun 3, 2026

    3mo ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001193125-26-253165

    Jun 2, 2026

    3mo ago

    Open filing
  • 4

    Statement of changes in beneficial ownership

    Accession 0001104659-26-068236

    May 29, 2026

    3mo ago

    Open filing
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001104659-26-067648

    May 28, 2026

    3mo ago

    Open filing
  • DEF 14A

    Definitive proxy statement

    Accession 0001104659-26-067017

    May 27, 2026

    3mo ago

    Open filing
  • 425

    Business-combination communication

    Accession 0001104659-26-066602

    May 27, 2026

    3mo ago

    Open filing
  • 8-K

    Entry into a material definitive agreement; Regulation FD disclosure

    Items 1.01, 7.01, 9.01 · Accession 0001104659-26-066599

    May 27, 2026

    3mo ago

    Open filing
  • 10-Q

    Quarterly report

    Accession 0001104659-26-061556

    May 15, 2026

    3mo ago

    Open filing
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0000886982-26-000255

    May 13, 2026

    3mo ago

    Open filing
  • 10-K/A

    10-K/A

    Accession 0001104659-26-058544

    May 11, 2026

    3mo ago

    Open filing

Translational Development Acquisition Corp.: questions answered

What is Translational Development Acquisition Corp. (TDAC)?

Translational Development Acquisition Corp. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0001926599. It completed its initial public offering in Dec 2024 and listing on Nasdaq. Class A shares trade under the ticker TDAC, units under TDACU, warrants under TDACW on Nasdaq. The vehicle is sponsored by TDAC through TDAC Partners LLC. The mandate targets generalist. Definitive business-combination agreement signed, closing pending.

How much does Translational Development Acquisition Corp. hold in trust?

Approximately $157,261,867, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Translational Development Acquisition Corp. complete a merger?

By Jun 24, 2027. If no combination closes by then the sponsor must seek a further extension or wind the vehicle up and return the trust.

What happens if Translational Development Acquisition Corp. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Translational Development Acquisition Corp., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Translational Development Acquisition Corp. trade under?

Class A shares trade as TDAC on Nasdaq, the units as TDACU, and the warrants as TDACW. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Translational Development Acquisition Corp.?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

How much dilution do Translational Development Acquisition Corp.'s founder shares and warrants create?

Each unit also carried one-half of one warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.

Who sponsors Translational Development Acquisition Corp., and what is their track record?

TDAC Partners LLC is the sponsor entity, part of the TDAC franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Michael B. Hoffman.

Which banks underwrote the Translational Development Acquisition Corp. IPO?

BTIG. BTIG was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is Translational Development Acquisition Corp. tradeable, and where?

Yes. TDAC returned a live quote of $10.87 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Translational Development Acquisition Corp. a good investment?

That is not a question this site answers. Translational Development Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Translational Development Acquisition Corp. data come from?

Filings Translational Development Acquisition Corp. submitted to the SEC under CIK 0001926599: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Sep 4, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.